These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8223981)

  • 21. Effect of bromocriptine in pituitary-dependent Cushing's syndrome.
    Boscaro M; Benato M; Mantero F
    Clin Endocrinol (Oxf); 1983 Oct; 19(4):485-91. PubMed ID: 6313262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endogenous dopaminergic inhibition of aldosterone and prolactin secretion is apparently not increased in primary aldosteronism.
    Jungmann E; Althoff PH; Rosak C; Schwedes U; Schöffling K
    Horm Metab Res; 1986 Feb; 18(2):138-40. PubMed ID: 3699687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of nocturnal elevation of plasma prolactin concentrations in Cushing's disease.
    Krieger DT; Howanitz PJ; Frantz AG
    J Clin Endocrinol Metab; 1976 Feb; 42(2):260-72. PubMed ID: 816805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldosterone content in plasma, erythrocytes and skeletal muscles in Icenko-Cushing's syndrome.
    Yakovlev HM; Yakovlev VA; Trofimov VM; Shustov SB; Vavilov AG
    Exp Clin Endocrinol; 1990 Nov; 96(2):138-42. PubMed ID: 2097160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum prolactin responses to metoclopramide in Cushing's syndrome and Nelson's syndrome.
    Kasperlik-Zaluska AA; Jeske W
    Acta Endocrinol (Copenh); 1980 Mar; 93(3):351-5. PubMed ID: 6246703
    [No Abstract]   [Full Text] [Related]  

  • 26. Reduction of pituitary tumor size with clinical and biochemical improvement with bromocriptine in a normoprolactinemic Cushing's disease.
    Hayashi H; Mercado-Asis LB; Murayama M; Yamakita N; Yasuda K; Miura K
    Endocrinol Jpn; 1990 Dec; 37(6):875-82. PubMed ID: 1966282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long term bromocriptine therapy in Cushing's disease.
    Kapcala LP; Jackson IM
    J Endocrinol Invest; 1982; 5(2):117-20. PubMed ID: 6284830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of metoclopramide and domperidone on aldosterone, 18-hydroxycorticosterone and prolactin secretion in the rhesus monkey.
    Sowers JR; Eggena P; Phillips D
    Metabolism; 1982 Dec; 31(12):1219-23. PubMed ID: 7144566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of captopril on the plasma aldosterone response to metoclopramide in normal subjects].
    Zachariéva S; Koev D; Tcharaktchiev D; Moskov M; Andonova K
    Ann Endocrinol (Paris); 1989; 50(3):233-6. PubMed ID: 2683976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bromocriptine in Nelson's syndrome and Cushing's disease.
    Lamberts SW; Birkenhäger JC
    Lancet; 1976 Oct; 2(7989):811. PubMed ID: 61490
    [No Abstract]   [Full Text] [Related]  

  • 31. Evidence for increased endogenous dopaminergic inhibition of aldosterone secretion in prolactinoma.
    Jungmann E; Schwedes U; Althoff PH; Rosak C; Schöffling K
    Horm Metab Res; 1986 Oct; 18(10):704-5. PubMed ID: 3781476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Aldosterone response to metoclopramide, a dopaminergic inhibitor, in normal men; evaluation of the mechanisms (author's transl)].
    Mizuno K; Yamazaki M; Toki T; Ono Y; Hashimoto S; Yaginuma K; Nagasawa S; Fukuchi S
    Nihon Jinzo Gakkai Shi; 1982 Feb; 24(2):175-80. PubMed ID: 7047824
    [No Abstract]   [Full Text] [Related]  

  • 33. Basal and saline-stimulated plasma atrial natriuretic hormone in Cushing's syndrome.
    McKnight JA; McCance DR; Roberts G; Sheridan B; Atkinson AB
    Acta Endocrinol (Copenh); 1991 Jan; 124(1):7-11. PubMed ID: 1825738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of metoclopramide and dopamine on plasma aldosterone concentration in normal man and rhesus monkeys (Macaca mulatta): a new model to study dopamine control of aldosterone secretion.
    Brown RD; Billman GE; Kem DC; Stone HL; Jiang NS; Kao P; Hegstad RL
    J Clin Endocrinol Metab; 1982 Nov; 55(5):828-32. PubMed ID: 7119085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma aldosterone response to metoclopramide is unmodified by hyperprolactinemia.
    Serri O
    Horm Res; 1987; 27(1):36-41. PubMed ID: 3623428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disparate effects of acute administration of dopamine receptor antagonists on plasma aldosterone and prolactin levels in the rat.
    Van der Niepen P; Dupont AG; Buydens P; Smitz JJ; Vanhaelst L
    Horm Metab Res; 1987 Jun; 19(6):279-80. PubMed ID: 3305273
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of metergoline on the aldosterone-stimulating properties of metoclopramide.
    Opocher G; Murgia A; Boscaro M; D'Agostino D; Fallo F; Mantero F
    J Steroid Biochem; 1983 Jul; 19(1B):531-6. PubMed ID: 6350721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dopaminergic control of aldosterone secretion in man (author's transl)].
    Suzuki H; Kasai K; Naitoh T; Nakamura T; Shina H; Ieiri T; Takemura Y; Shimoda S
    Nihon Naibunpi Gakkai Zasshi; 1980 Jul; 56(7):973-82. PubMed ID: 7007104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homocysteine, renin and aldosterone in patients with Cushing's syndrome.
    Zacharieva S; Kirilov G; Orbetzova M; Elenkova A; Shigarminova R; Lozanov V; Mitev V
    Methods Find Exp Clin Pharmacol; 2008 Apr; 30(3):221-4. PubMed ID: 18597007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do weak mineralocorticoids affect the pathogenesis of hypertension in Cushing's disease?
    Hermus A; Hobma S; Pieters G; Benraad T; Smals A; Kloppenborg P
    J Hypertens Suppl; 1989 Dec; 7(6):S208-9. PubMed ID: 2698926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.